康艾注射液辅助替吉奥治疗晚期非小细胞肺癌疗效及对血清VEGF、P53及抗Survivin抗体表达的影响  

The curative effect of Kang'ai injection combined with S- 1 in the treatment of advanced non-small cell lung cancer and its influence on the expression of serum VEGF,P53 and anti-survivin antibody

作　　者：杨君[1] 韩莹[1] 郭晓辉[1] 王爱辉[2] 李明宇[1] 

机构地区：[1]河北港口集团有限公司港口医院,河北秦皇岛066000 [2]河北省秦皇岛市第三医院,河北秦皇岛066000

出　　处：《现代中西医结合杂志》2016年第18期1970-1973,2046,共5页Modern Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的探讨康艾注射液辅助替吉奥治疗一、二线化疗方案治疗后复发或出现药物抵抗的晚期非小细胞肺癌的近期疗效及对血清VEGF、P53抗体及抗survivin抗体表达的影响。方法将60例晚期非小细胞肺癌患者随机分为观察组和对照组,对照组给予替吉奥单药治疗,观察组加用康艾注射液治疗,观察2组治疗前后血清VEGF、P53抗体、抗Survivin抗体水平及阳性表达情况,统计2组近期疗效、临床受益率及毒副反应发生情况。结果治疗后,观察组血清VEGF、P53及抗Survivin抗体水平及对照组血清VEGF、抗Survivin抗体水平均明显低于治疗前(P均<0.05),且观察组血清VEGF水平明显低于对照组(P<0.05),2组P53及抗Survivin抗体水平比较差异均无统计学意义(P均>0.05);2组治疗前后各指标阳性率比较差异均无统计学意义(P均>0.05)。疗程结束后,2组疗效比较差异无统计学意义(P>0.05);治疗结束后4周进行随访,观察组临床受益率有高于对照组的趋势,但差异无统计学意义(P>0.05)。治疗过程中,观察组严重毒副反应总发生率明显低于对照组(P<0.05)。结论替吉奥联合康艾注射液治疗一、二线化疗方案治疗后复发或出现药物抵抗的晚期非小细胞肺癌患者,虽然不能明显提高近期疗效,但能明显改善血清VEGF、P53抗体及抗Survivin抗体水平,降低不良反应发生率,有利于提高患者治疗的依从性,改善生存质量。Objective It is to investigate the curative effect of Kang＇ai injection combined with S- 1 in the treatment of advanced non-small cell lung cancer（ NSCLC） patients which relapse or drug resistance after one-,second-line chemotherapy regimen,and observe its influence on the expression of serum VEGF,P53 antibody and anti-survivin antibody. Methods 60 cases of advanced NSCLC patients were randomly divided into observation group and control group. The patients were treated with S- 1 monotherapy in the control group,and with Kang＇ai injection in the observation group combined with S- 1. The levels of serum vascular endothelial growth factor（ VEGF）,P53 antibody and anti-survivin antibody and their positive expression were observed in the 2 groups before and after treatment,and the recently curative effect,clinical benefit rate and adverse reaction were recorded. Results After treatment,the serum levels of VEGF,P53 and anti-survivin antibody of the observation group and the levels of VEGF,anti-survivin antibody of the control group were significantly lower than those before treatment（ all P 0. 05）,and the serum VEGF level of the observation group was significantly lower than that of the control group（ P 0. 05）,there was no significant difference in the levels of P53 and anti-survivin antibody between the two groups（ all P 0. 05）; there was no significant difference in positive rate of various index of the two groups before and after treatment（ all P 0. 05）. After the end of treatment,there was no significant difference in curative effect between the two groups（ P 0. 05）;the end of treatment after 4 weeks of follow-up,the clinical benefit rate of the observation group were higher than those of the control group,but there was no significant difference（ P 0. 05）. During the course of treatment,the total incidence of severe toxicity in the observation group was significantly lower than that in the control group（ P 0. 05）. Conclusion The treatment of Kang＇ai injection combined with S

关 键 词：康艾注射液 替吉奥 非小细胞肺癌 VEGF P53抗体 抗Survivin抗体 

分 类 号：R734.2[医药卫生—肿瘤]